Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05741593

Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated with Antithrombotics for an Ischemic Stroke.

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

institute of aging - Hôpital des Charpennes

Villeurbanne, 69100, France

Location status: Recruiting

Location contact

Teddy NOVAIS, PharmD, PhD

CONTACT

About this study

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. The probability of stroke recurrence is high: about 25% the first year , and 30 to 40% in the 5 years following the stroke. Recurrent strokes are responsible for significant disability, institutionalization, major neurocognitive disorders, and death.

In order to reduce the risk of stroke recurrence, multiple secondary prevention strategies have demonstrated their effectiveness, such as the prescription of drugs (in particular statins and antithrombotics), the establishment of a balanced diet, the practice of an activity physical, or even tobacco addiction.

However, the effectiveness of these strategies is optimal if and only if patients adhere to them.

In addition, previous studies have focused on the brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

In elderly patients, other obstacles could have been identified by specific studies, such as cognitive, sensory, functional disorders or even isolation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 65 and over
  • Patients hospitalized for an ischemic stroke or a recurrence of ischemic stroke, already being treated with an antithrombotic treatment (antiplatelet agent or anticoagulant ) prior to the stroke
  • Patients living at home and with a plan to return home.
  • Patients who did not object to the study and who gave their consent for the recording of the interview

Exclusion criteria

  • Patients with cognitive disorders or stroke sequelae that do not allow a semi-directive interview to be carried out (at medical discretion).
  • Non-French speaking patients

Treatment and study plan

Analysis of the verbatim from the transcription of the recorded interviews.

Other

recorded semi-structured interviews between the patients and the pharmacist

Primary outcomes

  1. Analysis of the verbatim from the transcription of the recorded interviews.

    Time frame: one year

    Describing the content of discussions, relating to antithrombotic treatment for secondary prevention, between elderly patients previously treated with antithrombotics and admitted to hospital for an ischemic stroke and a pharmacist

Secondary outcomes

  1. Analysis of verbatim statements from the transcription of recorded interviews on patients' representations and beliefs regarding antithrombotics

    Time frame: 15 to 60 minutes per patient

    Exploring patients' representations and beliefs regarding antithrombotics before and after the onset of stroke or recurrence of stroke

  2. Analysis of verbatim statements from the transcription of recorded interviews on patients' medication adherence to antithrombotics

    Time frame: 15 to 60 minutes per patient

    Explore patients' medication adherence to antithrombotics before the onset of stroke or recurrence of stroke

  3. Analysis of verbatim statements from the transcription of recorded interviews on the impact of the occurrence of stroke or recurrence of stroke on medication adherence

    Time frame: 15 to 60 minutes per patient

    Explore the impact of stroke occurrence or stroke recurrence on patient medication adherence (including motivation, ambivalence, confidence in medication benefits)

  4. Analysis of verbatim statements from the transcription of recorded interviews on the obstacles and levers to medication adherence

    Time frame: 15 to 60 minutes per patient

    Identify the barriers and levers to drug adherence with antithrombotics

Study contacts

Contact information is provided by the study sponsor or research team.

Teddy Novais, PharmD, PhD

CONTACT

[email protected]

+33472432155

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: QUATRO

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 23, 2023
Registry last updated
Nov 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.